References
Key articles
Stephenson A, Bass EB, Bixler BR, et al. Diagnosis and treatment of early-stage testicular cancer: AUA guideline amendment 2023. J Urol. 2024 Jan;211(1):20-5.Full text Abstract
European Association of Urology. Testicular cancer. 2023 [internet publication].Full text
Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-75.Full text Abstract
American College of Radiology. ACR appropriateness criteria: staging and surveillance of testicular cancer. 2021 [internet publication].Full text
Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021 May 10;39(14):1563-74.Full text Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: testicular cancer [internet publication].Full text
Reference articles
1. Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin North Am. 2018 Mar;102(2):251-64. Abstract
2. Stephenson A, Bass EB, Bixler BR, et al. Diagnosis and treatment of early-stage testicular cancer: AUA guideline amendment 2023. J Urol. 2024 Jan;211(1):20-5.Full text Abstract
3. World Health Organization. WHO classification of tumours. Urinary and male genital tumours. 5th ed. vol 8. Lyon, France: IARC Press; 2022.
4. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016 Jul;70(1):93-105. Abstract
5. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022 Nov;82(5):458-68.Full text Abstract
6. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.
7. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC). TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.
8. Shah YB, Goldberg H, Hu B, et al. Metastatic testicular cancer patterns and predictors: a contemporary population-based SEER analysis. Urology. 2023 Oct;180:182-9.Full text Abstract
9. Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol. 2010 Jan;21(1):104-8. Abstract
10. Daniels IR, Layer GT. Testicular tumours presenting as gynaecomastia. Eur J Surg Oncol. 2003 Jun;29(5):437-9. Abstract
11. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.Full text Abstract
12. Znaor A, Lortet-Tieulent J, Laversanne M, et al. International testicular cancer incidence trends: generational transitions in 38 countries 1900-1990. Cancer Causes Control. 2015 Jan;26(1):151-8. Abstract
13. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: testicular cancer. 2023 [internet publication].Full text
14. Gurney JK, Florio AA, Znaor A, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019 Nov;76(5):615-23. Abstract
15. Huang J, Chan SC, Tin MS, et al. Worldwide distribution, risk factors, and temporal trends of testicular cancer incidence and mortality: a global analysis. Eur Urol Oncol. 2022 Oct;5(5):566-76. Abstract
16. DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019 May;69(3):211-33.Full text Abstract
17. Schaffar R, Pant S, Bouchardy C, et al. Testicular cancer in Geneva, Switzerland, 1970-2012: incidence trends, survival and risk of second cancer. BMC Urol. 2019 Jul 10;19(1):64.Full text Abstract
18. Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. BMJ. 2022 Nov 28;379:e070499.Full text Abstract
19. Berney DM, Cree I, Rao V, et al. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology. 2022 Oct;81(4):459-66.Full text Abstract
20. Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet. 2017 Jul;49(7):1141-7.Full text Abstract
21. Singla N, Lafin JT, Ghandour RA, et al. Genetics of testicular germ cell tumors. Curr Opin Urol. 2019 Jul;29(4):344-9. Abstract
22. Cheng L, Albers P, Berney DM, et al. Testicular cancer. Nat Rev Dis Primers. 2018 Oct 5;4(1):29. Abstract
23. Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018 Apr;25(4):337-44.Full text Abstract
24. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284-297. Abstract
25. Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology. 2006;67:594-598. Abstract
26. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999-7004. Abstract
27. Ferguson L, Agoulnik AI. Testicular cancer and cryptorchidism. Front Endocrinol (Lausanne). 2013;4:32.Full text Abstract
28. Yazici S, Del Biondo D, Napodano G, et al. Risk factors for testicular cancer: environment, genes and infections-is it all? Medicina (Kaunas). 2023 Apr 7;59(4):724.Full text Abstract
29. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005 Feb;18 Suppl 2:S51-60. Abstract
30. Loveday C, Law P, Litchfield K, et al. Large-scale analysis demonstrates familial testicular cancer to have polygenic aetiology. Eur Urol. 2018 Sep;74(3):248-52.Full text Abstract
31. Richiardi L, Akre O, Montgomery SM, et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst. 2004 Jan 21;96(2):145-7.Full text Abstract
32. Dong C, Lonnstedt I, Hemminki K Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer. 2001 Oct;37(15):1878-85. Abstract
33. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997 Nov 15;80(10):1954-60. Abstract
34. Zequi Sde C, da Costa WH, Santana TB, et al. Bilateral testicular germ cell tumours: a systematic review. BJU Int. 2012 Oct;110(8):1102-9. Abstract
35. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007853. Abstract
36. Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst. 2001 Apr 4;93(7):545-51.Full text Abstract
37. Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003 May 15;21(10):1922-7. Abstract
38. Kulacoglu H, Köckerling F. Hernia and cancer: the points where the roads intersect. Front Surg. 2019;6:19.Full text Abstract
39. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007 May 3;356(18):1835-41.Full text Abstract
40. Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med. 2012 Apr;136(4):435-46. Abstract
41. Dogra V, Bhatt S. Acute painful scrotum. Radiol Clin North Am. 2004 Mar;42(2):349-63. Abstract
42. Marcell AV, Bell DL, Joffe A; Society for Adolescent Health and Medicine, SAHM Male Health Special Interest Group. The male genital examination: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health. 2012 Apr;50(4):424-5. Abstract
43. Richie JP. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campell's urology. 7th ed. Philadelphia, PA: WB Saunders Company; 2001:2417-8.
44. American College of Radiology. ACR appropriateness criteria: newly diagnosed palpable scrotal abnormality. 2021 [internet publication].Full text
45. European Association of Urology. Testicular cancer. 2023 [internet publication].Full text
46. Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-75.Full text Abstract
47. Sohaib SA, Cook G, Koh DM. Imaging studies for germ cell tumors. Hematol Oncol Clin North Am. 2011 Jun;25(3):487-502, vii. Abstract
48. American College of Radiology. ACR appropriateness criteria: staging and surveillance of testicular cancer. 2021 [internet publication].Full text
49. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.Full text Abstract
50. Milose JC, Filson CP, Weizer AZ, et al. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol. 2011 Dec 30;4:1-8.Full text Abstract
51. Dieckmann KP, Radtke A, Geczi L, et al. Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019 Jun 1;37(16):1412-23.Full text Abstract
52. Nestler T, Schoch J, Belge G, et al. MicroRNA-371a-3p-the novel serum biomarker in testicular germ cell tumors. Cancers (Basel). 2023 Aug 3;15(15):3944.Full text Abstract
53. Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer. 2002 Sep 15;95(6):1228-33. Abstract
54. Street E, Joyce A, Wilson J. BASHH UK guideline for the management of epididymo-orchitis, 2010. Int J STD AIDS. 2011 Jul;22(7):361-5.Full text Abstract
55. Hassan MA. Presentation and management outcome of symptomatic epididymal cysts in children: a case series. Int J Surg Open. 2023;55:100626.Full text
56. Kingston M, French, Higgins S, et al. UK national guidelines on the management of syphilis 2015. Int J STD AIDS. 2016 May;27(6):421-46.Full text Abstract
57. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb;15(2):594-603.Full text Abstract
58. Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021 May 10;39(14):1563-74.Full text Abstract
59. Beyer J, Collette L, Sauvé N, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol. 2021 May 10;39(14):1553-62.Full text Abstract
60. US Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2011 Apr 5;154(7):483-6.Full text Abstract
61. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: testicular cancer [internet publication].Full text
62. Ruf CG, Schmidt S, Kliesch S, et al. Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol. 2022 Dec;40(12):2889-2900.Full text Abstract
63. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005 Dec 20;23(36):9290-4. Abstract
64. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011 Feb 2;103(3):241-9.Full text Abstract
65. Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66.Full text Abstract
66. Aydin AM, Zemp L, Cheriyan SK, et al. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan;9(suppl 1):S36-44.Full text Abstract
67. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol (Meeting Abstracts). 2005;23(suppl 16):abstr 4520.
68. Petrelli F, Coinu A, Cabiddu M, et al. Surveillance or adjuvant treatment with chemotherapy or radiotherapy in stage I seminoma: a systematic review and meta-analysis of 13 studies. Clin Genitourin Cancer. 2015 Oct;13(5):428-34. Abstract
69. Patel HD, Srivastava A, Alam R, et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol. 2017 Oct;35(10):606.e1-7. Abstract
70. Hamilton RJ, Canil C, Shrem NS, et al. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. Can Urol Assoc J. 2022 Jun;16(6):155-73.Full text Abstract
71. Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol. 2021 Nov 15 [Epub ahead of print].Full text Abstract
72. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma. J Clin Oncol. 1999 Apr;17(4):1146. Abstract
73. Chung P, Warde P. Testicular cancer: germ cell tumours. BMJ Clin Evid. 2016 Jan 7;2016. pii: 1807.Full text Abstract
74. Cohn-Cedermark G, Stahl O, Tandstad T, et al. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology. 2015 Jan;3(1):102-10.Full text Abstract
75. Tyrrell HEJ, Church DN, Joseph J, et al. Changing practice evaluation-stage 1 seminoma: outcomes with adjuvant treatment versus surveillance: risk factors for recurrence and optimizing follow-up protocols-experience from a supraregional center. Clin Genitourin Cancer. 2018 Jun;16(3):240-4. Abstract
76. Chung P, Mayhew LA, Warde P, et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol). 2010 Feb;22(1):6-16. Abstract
77. Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014 Dec 1;32(34):3817-23. Abstract
78. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003 Jan;111(1):76-83. Abstract
79. Brewster SF. Challenging the EAU 2009 guidelines on testis cancer: the risk-adapted management of stage I nonseminomatous germ cell tumours: surveillance yields equal results with less toxicity. Euro Urol. 2010 Apr;9(3):459-61.Full text
80. Cullen M, Huddart R, Joffe J, et al. The 111 study: a single-arm, phase 3 trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis. Eur Urol. 2020 Mar;77(3):344-51.Full text Abstract
81. Calabrò F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012 Jun;61(6):1212-21. Abstract
82. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors. J Clin Oncol. 1989 Mar;7(3):387-91. Abstract
83. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide with either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors. J Clin Oncol. 1998 Apr;16(4):1287-93. Abstract
84. Bokemeyer C, Schmoll HJ, Ludwig E, et al. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer. 1994 May;69(5):863-7.Full text Abstract
85. Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec;15(13):1442-50.Full text Abstract
86. Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012 Nov;62(5):867-76. Abstract
87. Cathomas R, Klingbiel D, Bernard B, et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group registry. J Clin Oncol. 2018 Oct 4;JCO1800210.Full text Abstract
88. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549-55.Full text Abstract
89. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 Oct 1;109(7):540-6. Abstract
90. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998 Jul;16(7):2500-4. Abstract
91. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage in patients with relapsed testicular cancer. J Clin Oncol. 2000 Oct 1;18(19):3346-51. Abstract
92. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012 Mar 10;30(8):800-5. Abstract
93. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706-13.Full text Abstract
94. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 Jul 26;357(4):340-8.Full text Abstract
95. McHugh DJ, Feldman DR. Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors. Adv Urol. 2018;2018:7272541.Full text Abstract
96. Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1165-73. Abstract
97. Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol. 1997 Aug;31(4):355-9. Abstract
98. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000 Jun;163(6):1721-4. Abstract
99. Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol. 2005 Sep;6(5):367-77. Abstract
100. Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 2004 Feb 1;22(3):464-7. Abstract
101. American Urological Association. AUA white paper on implementation of shared decision making into urological practice. 2022 [internet publication].Full text
102. Mazumdar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001 May 1;19(9):2534-41. Abstract
103. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003 Jun 15;97(12):3090-8. Abstract
104. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011 Sep;60(3):516-26. Abstract
105. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Jul 1;36(19):1994-2001.Full text Abstract
106. Lauritsen J, Hansen MK, Bandak M, et al. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol. 2020 Feb 20;38(6):584-592.Full text Abstract
107. Lubberts S, Groot HJ, de Wit R, et al. Cardiovascular disease in testicular cancer survivors: identification of risk factors and impact on quality of life. J Clin Oncol. 2023 Jul 1;41(19):3512-22.Full text Abstract
108. Shrem NS, Wood L, Hamilton RJ, et al. Testicular cancer survivorship: long-term toxicity and management. Can Urol Assoc J. 2022 Aug;16(8):257-72. Abstract
109. Groot HJ, Lubberts S, de Wit R, et al. Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol. 2018 Aug 20;36(24):2504-13.Full text Abstract
Use of this content is subject to our disclaimer